Cytek Biosciences
CTKB
129 hedge funds and large institutions have $425M invested in Cytek Biosciences in 2024 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 56 increasing their positions, 40 reducing their positions, and 16 closing their positions.
40% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 40
31% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 16
3% more funds holding
Funds holding: 125 → 129 (+4)
3.57% less ownership
Funds ownership: 61.61% → 58.04% (-3.6%)
21% less capital invested
Capital invested by funds: $541M → $425M (-$116M)
83% less call options, than puts
Call options by funds: $1K | Put options by funds: $6K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$5.52M |
| 2 |
Goldman Sachs
New York
|
+$4.76M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$4.69M |
| 4 |
JP Morgan Chase
New York
|
+$3.14M |
| 5 |
Renaissance Technologies
New York
|
+$1.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$45.7M |
| 2 |
BCM
Brown Capital Management
Baltimore,
Maryland
|
-$3.81M |
| 3 |
DSCM
Divisadero Street Capital Management
Miami,
Florida
|
-$3.27M |
| 4 |
BlackRock
New York
|
-$2.14M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.6M |
CTKB Hedge Fund Activity: Q2 2024 in Review
129 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Cytek Biosciences (CTKB) for Q2 2024, worth a combined $425M — down 21% from $541M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new CTKB positions and 16 closed out — a net gain of 5 holders — while 56 added to existing stakes and 40 trimmed.
The largest buyer was Millennium Management, adding an estimated $5.52M. The largest seller was RA Capital Management, exiting entirely with an estimated $45.7M sold.
- 129 institutional investors held Cytek Biosciences (CTKB) as of Q2 2024, up from 125 in Q1 2024.
- Funds reported $425M of Cytek Biosciences stock for Q2 2024, down 21% quarter-over-quarter.
- 21 funds opened new Cytek Biosciences positions in Q2 2024 and 16 closed out, a net change of +5 holders.
- The largest Cytek Biosciences buyer in Q2 2024 was Millennium Management, an estimated $5.52M added.
- The largest Cytek Biosciences seller in Q2 2024 was RA Capital Management, an estimated $45.7M sold.
Based on aggregated 13F filings for Q2 2024.